Sanofi-Aventis Raises Genzyme Bid

France’s Sanofi-Aventis has agreed to raise its bid for Genzyme (GENZ) to the low $70’s per share range, plus a milestone payment based on the performance of an experimental drug, a source familiar with the situation told Reuters on Tuesday.

Jasper - The Real Deal!

Be the first to comment

Leave a Reply

Your email address will not be published.


This site uses Akismet to reduce spam. Learn how your comment data is processed.